Organon & Co. (OGN)
| Market Cap | 1.86B |
| Revenue (ttm) | 6.30B |
| Net Income (ttm) | 501.00M |
| Shares Out | 259.98M |
| EPS (ttm) | 1.91 |
| PE Ratio | 3.73 |
| Forward PE | 1.90 |
| Dividend | $0.08 (1.12%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 3,321,347 |
| Open | 7.14 |
| Previous Close | 7.14 |
| Day's Range | 7.04 - 7.19 |
| 52-Week Range | 6.18 - 17.23 |
| Beta | 0.54 |
| Analysts | Hold |
| Price Target | 15.75 (+120.59%) |
| Earnings Date | Nov 10, 2025 |
About OGN
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]
Financial Performance
In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OGN stock is "Hold." The 12-month stock price target is $15.75, which is an increase of 120.59% from the latest price.
News
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.
Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect
Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, a...
Organon Analysts Cut Their Forecasts Following Q3 Results
Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.
Organon & Co. (OGN) Q3 2025 Earnings Call Transcript
Organon & Co. ( OGN) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP an...
Organon Reports Results for the Third Quarter Ended September 30, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this ...
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.
The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products
Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 p...
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings...
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices
Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplano...
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufa...
Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy
Organon remains a buy as the stock trades at distressed valuations despite stable fundamentals and progress on debt reduction. OGN's Women's Health and Biosimilars segments drive growth, offsetting re...
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars.
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).
Organon: Valuation Discount Offset By Structural Headwinds
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines...
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new produc...
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of R...
Organon Reports Results for the Second Quarter Ended June 30, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon shares results for second quarter ended June 30, 2025.
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to report second quarter 2025 results and host conference call on August 5, 2025.
OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal s...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options